Previous 10 | Next 10 |
EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response compared to Comirnaty® and superiority of ARCT-154 in neutralizing antibody response aga...
2023-08-14 10:06:41 ET More on Arcturus Therapeutics Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race Arcturus down 18% on disappointing Q2 results Arcturus Therapeutics receives FDA fast track status for ARCT-810 Arcturus raised t...
LUNAR-FLU collaboration with CSL Seqirus achieves additional $17.5 million development milestone Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the devel...
2023-08-08 14:39:05 ET Shares of Arcturus Therapeutics (NASDAQ: ARCT) fell more than 18% as of 2:15 p.m. ET on Tuesday. The clinical-stage biotech company announced second-quarter earnings after the markets closed on Monday. The stock is still up more than 52% this year. Arc...
2023-08-08 10:21:19 ET Gainers: Bright Minds Biosciences ( DRUG ) +62% . Bionomics ( BNOX ) +24% . Novo Nordisk ( NVO ) +18% . Quanterix ( QTRX ) +17% . Tilray Brands ( TLRY ) +18% . Losers: Vistagen Therapeutics ( VTGN ...
2023-08-07 20:18:04 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Neda Safarzadeh - VP, Head IR, Public Relations and Marketing Joseph Payne - President and CEO Andy Sassine - CFO ...
2023-08-07 16:17:08 ET Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q2 GAAP EPS of -$1.98 misses by $1.81 . Revenue of $10.52M (-61.2% Y/Y) misses by $38.81M . Cash, cash equivalents and restricted cash were $380.6 million as of June 30, 2023 and $394....
ARCT-154 Phase 3 COVID-19 booster trial achieved primary endpoint demonstrating strong immune response and favorable safety profile Meiji Seika Pharma submitted ARCT-154 New Drug Application in Japan New ARCT-154 booster clinical data demonstrate one-year durability across a panel...
Arcturus to present at the Canaccord Genuity 43 rd Annual Growth Conference , August 9, 2023 Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the dev...
2023-07-18 06:22:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry’s research and development. Large biotech companies such as Johnson and Johnso...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...